{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:36:20Z","timestamp":1787060180112,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA279916-01A1"],"award-info":[{"award-number":["CA279916-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Differential expression of Kallikreins (KLKs) was described for established metastatic pancreatic ductal adenocarcinoma (PDAC), but their potential as markers for early detection is not known. We have performed comprehensive in silico and\n                    <jats:italic>in situ<\/jats:italic>\n                    analyses of KLK expression in PDAC at different stages of tumor development. We found that upregulation of KLK7 and KLK10 RNA and protein occurs early in tumor development and marks carcinoma in-situ lesions (stage 0, PanIN3) and early-stage (stage 1) PDAC, while non-cancerous low grade lesions stain negative for these proteases. Moreover, both KLKs are co-expressed with desmoglein-3 (DSG3) in PDAC cell lines as well as PDAC samples from treatment na\u00efve patients. DSG3 serves as a substrate for both KLK7 and KLK10 resulting in a 30\u00a0kDa extracellular fragment. Overall, our data suggest that analyses for expression of KLK7 and KLK10 as well as their substrates could have potential as diagnostic biomarkers to distinguish non-cancerous low-grade lesions from earliest cancerous lesions in the pancreas.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-48628-7","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:03:41Z","timestamp":1776117821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kallikrein related peptidases 7 and 10 and their substrate desmoglein 3 are upregulated in early stage pancreatic cancerous lesions"],"prefix":"10.1038","volume":"16","author":[{"given":"Jillian","family":"Eisenhauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Argo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K. Fleming","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Maldosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia I.","family":"Bastea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody J.","family":"Wehrkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike R.","family":"D\u00f6ppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy H.","family":"Edenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Storz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"48628_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345. https:\/\/doi.org\/10.3322\/caac.21871 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"48628_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq3110","volume":"17","author":"JL Montoya Mira","year":"2025","unstructured":"Montoya Mira, J. L. et al. Early detection of pancreatic cancer by a high-throughput protease-activated nanosensor assay. Sci. Transl. Med. 17, eadq3110. https:\/\/doi.org\/10.1126\/scitranslmed.adq3110 (2025).","journal-title":"Sci. Transl. Med."},{"key":"48628_CR3","doi-asserted-by":"publisher","first-page":"9127","DOI":"10.1074\/jbc.M110.191361","volume":"286","author":"R Jiang","year":"2011","unstructured":"Jiang, R., Shi, Z., Johnson, J. J., Liu, Y. & Stack, M. S. Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma. J. Biol. Chem. 286, 9127\u20139135. https:\/\/doi.org\/10.1074\/jbc.M110.191361 (2011).","journal-title":"J. Biol. Chem."},{"key":"48628_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.biochi.2015.09.023","volume":"122","author":"M Kalinska","year":"2016","unstructured":"Kalinska, M., Meyer-Hoffert, U., Kantyka, T. & Potempa, J. Kallikreins - The melting pot of activity and function. Biochimie 122, 270\u2013282. https:\/\/doi.org\/10.1016\/j.biochi.2015.09.023 (2016).","journal-title":"Biochimie"},{"key":"48628_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbplus.2019.100019","volume":"6\u20137","author":"P Nauroy","year":"2020","unstructured":"Nauroy, P. & Nystrom, A. Kallikreins: Essential epidermal messengers for regulation of the skin microenvironment during homeostasis, repair and disease. Matrix Biol. Plus 6\u20137, 100019. https:\/\/doi.org\/10.1016\/j.mbplus.2019.100019 (2020).","journal-title":"Matrix Biol. Plus"},{"key":"48628_CR6","doi-asserted-by":"publisher","first-page":"17179","DOI":"10.1074\/jbc.M113.476820","volume":"288","author":"J Sakabe","year":"2013","unstructured":"Sakabe, J. et al. Kallikrein-related peptidase 5 functions in proteolytic processing of profilaggrin in cultured human keratinocytes. J. Biol. Chem. 288, 17179\u201317189. https:\/\/doi.org\/10.1074\/jbc.M113.476820 (2013).","journal-title":"J. Biol. Chem."},{"key":"48628_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/946572","volume":"2015","author":"AC Stefanini","year":"2015","unstructured":"Stefanini, A. C., da Cunha, B. R., Henrique, T. & Tajara, E. H. Involvement of kallikrein-related peptidases in normal and pathologic processes. Dis. Markers 2015, 946572. https:\/\/doi.org\/10.1155\/2015\/946572 (2015).","journal-title":"Dis. Markers"},{"key":"48628_CR8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nrc1474","volume":"4","author":"CA Borgono","year":"2004","unstructured":"Borgono, C. A. & Diamandis, E. P. The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876\u2013890. https:\/\/doi.org\/10.1038\/nrc1474 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"48628_CR9","doi-asserted-by":"publisher","first-page":"8911","DOI":"10.1021\/jacs.1c03950","volume":"143","author":"S Lovell","year":"2021","unstructured":"Lovell, S. et al. A suite of activity-based probes to dissect the KLK activome in drug-resistant prostate cancer. J. Am. Chem. Soc. 143, 8911\u20138924. https:\/\/doi.org\/10.1021\/jacs.1c03950 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"48628_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bbrc.2018.03.194","volume":"499","author":"XY Cao","year":"2018","unstructured":"Cao, X. Y. et al. Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK\/SRC\/ERK axis in PDAC. Biochem. Biophys. Res. Commun. 499, 584\u2013593. https:\/\/doi.org\/10.1016\/j.bbrc.2018.03.194 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"48628_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100871","volume":"36","author":"J Werner","year":"2023","unstructured":"Werner, J. et al. Targeted and explorative profiling of kallikrein proteases and global proteome biology of pancreatic ductal adenocarcinoma, chronic pancreatitis, and normal pancreas highlights disease-specific proteome remodelling. Neoplasia 36, 100871. https:\/\/doi.org\/10.1016\/j.neo.2022.100871 (2023).","journal-title":"Neoplasia"},{"key":"48628_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2012.07.024","volume":"22","author":"CM Ardito","year":"2012","unstructured":"Ardito, C. M. et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22, 304\u2013317. https:\/\/doi.org\/10.1016\/j.ccr.2012.07.024 (2012).","journal-title":"Cancer Cell"},{"key":"48628_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/MPA.0b013e31817f76f7","volume":"37","author":"VC Ramani","year":"2008","unstructured":"Ramani, V. C. & Haun, R. S. Expression of kallikrein 7 diminishes pancreatic cancer cell adhesion to vitronectin and enhances urokinase-type plasminogen activator receptor shedding. Pancreas 37, 399\u2013404. https:\/\/doi.org\/10.1097\/MPA.0b013e31817f76f7 (2008).","journal-title":"Pancreas"},{"key":"48628_CR14","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.bbrc.2008.03.021","volume":"369","author":"VC Ramani","year":"2008","unstructured":"Ramani, V. C. & Haun, R. S. The extracellular matrix protein fibronectin is a substrate for kallikrein 7. Biochem. Biophys. Res. Commun. 369, 1169\u20131173. https:\/\/doi.org\/10.1016\/j.bbrc.2008.03.021 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"48628_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-373","volume":"8","author":"VC Ramani","year":"2008","unstructured":"Ramani, V. C., Hennings, L. & Haun, R. S. Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer. BMC Cancer 8, 373. https:\/\/doi.org\/10.1186\/1471-2407-8-373 (2008).","journal-title":"BMC Cancer"},{"key":"48628_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrc2351","volume":"8","author":"H Lilja","year":"2008","unstructured":"Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat. Rev. Cancer 8, 268\u2013278. https:\/\/doi.org\/10.1038\/nrc2351 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"48628_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-014-0109-z","volume":"7","author":"A Tamir","year":"2014","unstructured":"Tamir, A. et al. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. J. Ovarian Res. 7, 109. https:\/\/doi.org\/10.1186\/s13048-014-0109-z (2014).","journal-title":"J. Ovarian Res."},{"key":"48628_CR18","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/sj.bjc.6604717","volume":"99","author":"F Ruckert","year":"2008","unstructured":"Ruckert, F. et al. Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. Br. J. Cancer 99, 1484\u20131492. https:\/\/doi.org\/10.1038\/sj.bjc.6604717 (2008).","journal-title":"Br. J. Cancer"},{"key":"48628_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53223-0","volume":"9","author":"LI Bastea","year":"2019","unstructured":"Bastea, L. I., Hollant, L. M. A., Doppler, H. R., Reid, E. M. & Storz, P. Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death. Sci. Rep. 9, 16588. https:\/\/doi.org\/10.1038\/s41598-019-53223-0 (2019).","journal-title":"Sci. Rep."},{"key":"48628_CR20","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.celrep.2017.04.052","volume":"19","author":"GY Liou","year":"2017","unstructured":"Liou, G. Y. et al. The presence of Interleukin-13 at pancreatic ADM\/PanIN lesions alters macrophage populations and mediates pancreatic tumorigenesis. Cell Rep. 19, 1322\u20131333. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.052 (2017).","journal-title":"Cell Rep."},{"key":"48628_CR21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678. https:\/\/doi.org\/10.1038\/s41587-020-0546-8 (2020).","journal-title":"Nat. Biotechnol."},{"key":"48628_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36296-4","volume":"14","author":"G Werba","year":"2023","unstructured":"Werba, G. et al. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat. Commun. 14, 797. https:\/\/doi.org\/10.1038\/s41467-023-36296-4 (2023).","journal-title":"Nat. Commun."},{"key":"48628_CR23","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1136\/gut.2010.236026","volume":"61","author":"CA Iacobuzio-Donahue","year":"2012","unstructured":"Iacobuzio-Donahue, C. A. Genetic evolution of pancreatic cancer: Lessons learnt from the pancreatic cancer genome sequencing project. Gut 61, 1085\u20131094. https:\/\/doi.org\/10.1136\/gut.2010.236026 (2012).","journal-title":"Gut"},{"key":"48628_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","volume":"148","author":"AD Rhim","year":"2012","unstructured":"Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349\u2013361. https:\/\/doi.org\/10.1016\/j.cell.2011.11.025 (2012).","journal-title":"Cell"},{"key":"48628_CR25","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nature09515","volume":"467","author":"S Yachida","year":"2010","unstructured":"Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114\u20131117. https:\/\/doi.org\/10.1038\/nature09515 (2010).","journal-title":"Nature"},{"key":"48628_CR26","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jnci\/djaa004","volume":"112","author":"AL Blackford","year":"2020","unstructured":"Blackford, A. L., Canto, M. I., Klein, A. P., Hruban, R. H. & Goggins, M. Recent trends in the incidence and survival of stage 1A pancreatic cancer: A Surveillance, Epidemiology, and End Results analysis. J. Natl. Cancer Inst. 112, 1162\u20131169. https:\/\/doi.org\/10.1093\/jnci\/djaa004 (2020).","journal-title":"J. Natl. Cancer Inst."},{"key":"48628_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/14737140.2020.1720654","volume":"20","author":"HC Crawford","year":"2020","unstructured":"Crawford, H. C., Wallace, M. B. & Storz, P. Early detection and imaging strategies to reveal and target developing pancreatic cancer. Expert Rev. Anticancer Ther. 20, 81\u201383. https:\/\/doi.org\/10.1080\/14737140.2020.1720654 (2020).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"48628_CR28","doi-asserted-by":"publisher","first-page":"12894","DOI":"10.18632\/oncotarget.24132","volume":"9","author":"JP Du","year":"2018","unstructured":"Du, J. P. et al. Kallikrein-related peptidase 7 is a potential target for the treatment of pancreatic cancer. Oncotarget 9, 12894\u201312906. https:\/\/doi.org\/10.18632\/oncotarget.24132 (2018).","journal-title":"Oncotarget"},{"key":"48628_CR29","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1373\/clinchem.2008.105189","volume":"54","author":"N Emami","year":"2008","unstructured":"Emami, N. & Diamandis, E. P. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin. Chem. 54, 1600\u20131607. https:\/\/doi.org\/10.1373\/clinchem.2008.105189 (2008).","journal-title":"Clin. Chem."},{"key":"48628_CR30","doi-asserted-by":"publisher","first-page":"29247","DOI":"10.18632\/oncotarget.16453","volume":"8","author":"T Shimura","year":"2017","unstructured":"Shimura, T. et al. Urinary kallikrein 10 predicts the incurability of gastric cancer. Oncotarget 8, 29247\u201329257. https:\/\/doi.org\/10.18632\/oncotarget.16453 (2017).","journal-title":"Oncotarget"},{"key":"48628_CR31","doi-asserted-by":"publisher","first-page":"9425","DOI":"10.3748\/wjg.v19.i48.9425","volume":"19","author":"X Jiao","year":"2013","unstructured":"Jiao, X. Overexpression of kallikrein gene 10 is a biomarker for predicting poor prognosis in gastric cancer. World J. Gastroenterol. 19, 9425\u20139431. https:\/\/doi.org\/10.3748\/wjg.v19.i48.9425 (2013).","journal-title":"World J. Gastroenterol."},{"key":"48628_CR32","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s13277-012-0368-5","volume":"33","author":"C Petraki","year":"2012","unstructured":"Petraki, C. et al. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumour Biol. 33, 1209\u20131214. https:\/\/doi.org\/10.1007\/s13277-012-0368-5 (2012).","journal-title":"Tumour Biol."},{"key":"48628_CR33","doi-asserted-by":"publisher","first-page":"17762","DOI":"10.1074\/jbc.M115.643551","volume":"290","author":"Y Yu","year":"2015","unstructured":"Yu, Y., Prassas, I., Dimitromanolakis, A. & Diamandis, E. P. Novel biological substrates of human kallikrein 7 identified through degradomics. J. Biol. Chem. 290, 17762\u201317775. https:\/\/doi.org\/10.1074\/jbc.M115.643551 (2015).","journal-title":"J. Biol. Chem."},{"key":"48628_CR34","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/cncr.22606","volume":"109","author":"SK Johnson","year":"2007","unstructured":"Johnson, S. K., Ramani, V. C., Hennings, L. & Haun, R. S. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer 109, 1811\u20131820. https:\/\/doi.org\/10.1002\/cncr.22606 (2007).","journal-title":"Cancer"},{"key":"48628_CR35","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.biochi.2010.06.022","volume":"92","author":"P Goettig","year":"2010","unstructured":"Goettig, P., Magdolen, V. & Brandstetter, H. Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie 92, 1546\u20131567. https:\/\/doi.org\/10.1016\/j.biochi.2010.06.022 (2010).","journal-title":"Biochimie"},{"key":"48628_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jid.2016.09.017","volume":"137","author":"SJ de Veer","year":"2017","unstructured":"de Veer, S. J. et al. Selective substrates and inhibitors for kallikrein-related peptidase 7 (KLK7) shed light on KLK proteolytic activity in the stratum corneum. J. Invest. Dermatol. 137, 430\u2013439. https:\/\/doi.org\/10.1016\/j.jid.2016.09.017 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"48628_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejmech.2015.02.008","volume":"93","author":"DP Arama","year":"2015","unstructured":"Arama, D. P. et al. Pyrido-imidazodiazepinones as a new class of reversible inhibitors of human kallikrein 7. Eur. J. Med. Chem. 93, 202\u2013213. https:\/\/doi.org\/10.1016\/j.ejmech.2015.02.008 (2015).","journal-title":"Eur. J. Med. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48628-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48628-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48628-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:41Z","timestamp":1780531241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48628-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["48628"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-48628-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17298"}}